Paraskevi Katsaounou1,*, Marios Ioannou1, Michael E Hyland2, Mikaela Odemyr3, Otto Spranger4, Anne Lindberg5, Matthias Gasser6, Lorena Garcia Conde7, Xavier Jaumont7 and Ismail Kasuje2

1First ICU Evangelismos Hospital, National and Kapodistrian University of Athens, 15341, Athens, Greece
2School of Psychology, University of Plymouth, Devon, United Kingdom
3European Federation of Allergy and Airways Diseases Patient’s Associations (EFA), Brussels, Belgium
4Global Allergy and Asthma Patient Platform (GAAPP), Vienna, Austria
5Department of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Sweden
6GfK Switzerland AG, Basel, Switzerland
7Novartis Pharma AG, Basel, Switzerland

Received: 22 November, 2019
Accepted: 08 December, 2019
Published: 09 December, 2019

*Corresponding author: Paraskevi Katsaounou, Assistant Professor of Respiratory Medicine, First ICU Evangelismos Hospital, National and Kapodistrian University of Athens, 20 Evagelisti Giavassiot; 15341, Athens, Greece. Tel: +30 6932668142; Fax: +30 2132043399; E-mail: paraskevikatsaounou@gmail.com

Keywords: Uncontrolled asthma; Smoking; Quality of life; Smoking asthmatics

Abstract

Introduction: Smoking in asthma patients is an important factor contributing to worsened control of asthma. Despite increased awareness of the harmful effects of smoking in patients with asthma, a significant proportion of asthmatics remain smokers. Here, we present findings from the Still Fighting for Breath global survey regarding the prevalence of smoking in patients with severe asthma, impact of smoking on asthma control and correlation of smoking with different aspects of quality of life in patients with severe persistent asthma.

Methods: This online survey conducted by GfK Switzerland in 2016 collected data from 1333 adults (>18 years) and caregivers of children (6–17 years) with severe persistent asthma in 9 countries.

Results: Our results showed that smoking was common in asthma patients with 46% of adult patients either current smoker (20%), ex-smoker (24%) or e-cigarette smokers (2%). The proportion of patients with asthma who were current smokers/ex-smokers or e-cigarette smokers was higher than in the general population in many countries. Overall, 63% of adult patients avoided smoky premises; however, 20% of adults were active smokers. Current smokers with asthma were significantly more frequently diagnosed with anxiety (47%) and depression (41%) than non-smokers (40% and 27%, respectively) and ex-smokers (42% and 28%, respectively). A positive correlation was observed between the number of days that patients with severe asthma used OCS and asthma control according to both the Global Initiative for Asthma (GINA)-defined control (Spearman’s rho=0.24, P<0.001) and patient-perceived control (Spearman’s rho=0.13, P<0.001).

Conclusion: This survey shows a high prevalence of smoking in patients with severe persistent asthma. Smoking was associated with increased risk of anxiety/depression and show slight increase in use of oral corticosteroid in these patients. These highlight the need for improved strategies for better management of the disease in smokers with severe persistent asthma.

Introduction

Uncontrolled asthma is a subset of asthma that remains inadequately controlled and symptomatic despite treatment with controllers such as high-dose inhaled glucocorticoids, or would need such a treatment to remain well controlled [1,2]. This phenotype of asthma is associated with increased exacerbations, hospitalizations and poorer Quality of Life (QoL).

Uncontrolled asthma can be aggravated by factors such as: co-morbidities including rhinitis, nasal polyposis, bronchiectasis, obesity, osteoporosis, depression and gastroesophageal reflux disease [3–6]. Lack of adherence to treatment, that may result in under-treatment of these patients [7]. Another important factor contributing to worsened control of asthma is smoking, in fact nicotine addiction is considered as a disease according to the Tenth Revision of the International Classification of Diseases and Health Problems (ICD–10) [8]. Smoking may result in worsening of asthma due to accelerated decline in lung function and increased symptoms [5,9]. Based on data from a population–based cohort with 15-year follow-up, Lemmetyinen, et al., suggests that high mortality in asthma patients may be due to smoking–induced excess loss of lung function leading to COPD [10]. Patients with asthma who are current smokers or ex–smokers are at a greater risk of hospitalization and emergency room visits when compared with never smokers [11]. A recent clinical study with a 12 years of follow-up reported a positive correlation between smoking and hospitalization, and a history of ≥20 pack–years was a significant predictor for respiratory–related hospitalization in adult–onset asthma [12]. Furthermore, psychological conditions such as anxiety and depression are often associated...
with smoking in patients with asthma, which may lead to worsening of the disease [13].

Oxidative stress is known to be involved in the pathogenesis of asthma and to trigger airway inflammation [14]. Asthma patients who smoke are likely to present increased oxidative stress that may incite airway inflammation [14,15]. An early characteristic of asthma is airway inflammation, which if untreated may cause airway remodeling leading to irreversible airflow obstruction [16]. Cigarette smoking in asthma patients may induce changes in the inflammatory pattern of the airways and asthma phenotype, including increased levels of neutrophils and IL-8 and decreased numbers of eosinophils compared to non-smoking asthma patients. This may lead to accelerated decline in lung function and increased severity of airflow obstruction in these patients [17-19]. These effects may result in reduced efficacy of available treatments in smoking asthmatics.

Treatment with Inhaled Corticosteroids (ICS) is the cornerstone of disease management across different severities of asthma and is recommended in patients with mild-to-severe persistent asthma [20]. However, cigarette smoking in patients with asthma is associated with steroid resistance, increasing asthma symptoms in these patients [21,22]. Studies have shown reduced efficacy of ICS in asthma patients who smoke, in terms of improvement in respiratory symptoms, forced expiratory volume in one second (FEV1), exacerbation rates and blood markers of inflammation compared with the non-smoking patients [19,21,23,24]. This poor response to ICS in smoking asthmatics is often associated with increased sputum neutrophil level and thus expressing neutrophilic inflammation that is not suppressed by ICS treatment as it suppresses eosinophilic inflammation [25]. Neutrophilia and oxidative stress as an asthma phenotype might be linked with TH17 inflammation and overexpression of IL-17 [26]. Other mechanisms accounting for corticosteroid insensitivity may include increase in tumor necrosis factor levels in smokers [27], which further leads to increase in number of glucocorticoid receptors [28], that have been associated with steroid resistance [21]. Moreover, cigarette smoke impairs histone deacetylase (HDAC) activity [29]. HDAC is recruited by glucocorticosteroids in order to suppress the transcription of inflammatory mediators [29].

High prevalence of psychological disorders, predominantly anxiety and depression have been reported in patients suffering from asthma [30-32]. Previous studies show a strong association between psychological disorders and poor asthma control [6,33,34]. Akula, et al., reported that diagnosis of asthma was associated with a history of mental health disorder, current clinically significant levels of depressive symptoms and a lifetime psychiatric disorder in a community-based study [35]. Psychological disorders may lead to mood disorders that may increase symptom perception in these patients, thus reducing the perception of asthma control [6]. Furthermore, certain symptoms of anxiety and depression such as shortness of breath, insomnia and fatigue may overlap with those of asthma and thus affect the evaluation of asthma control in these patients [36]. A high prevalence of undiagnosed psychological disorders, particularly depression have also been reported in patients with difficult to control asthma, which may increase the risk of deaths due to asthma in these patients [6,37,38].

Passive smoking via exposure to secondhand cigarette smoke may increase the risk of development or augmentation of asthma [39-42]. The prevalence of asthma in men and women is associated with indoor passive smoking exposure at home [43]. Children with asthma exposed to passive smoking experienced worse lung function parameters, more visits to emergency departments, lower oxygen saturation levels on admission, higher scores on the asthma exacerbation severity scale [44]. A study in a large population with 16 years of follow-up showed that passive smoking elevated the risk of developing asthma, even in participants who never experienced active smoking [39]. Furthermore, Hollams, et al., reported that maternal smoking in pregnancy increased the risk of asthma and wheezing in adolescent children [45]. A large Spanish cohort study showed that completely banning smoking in hospitality venues significantly decreased salivary cotinine and reduced the reported respiratory symptoms in hospitality workers. However, other measures like creating smoking areas and partially restrict smoking did not protect these workers against the harmful effects of secondhand smoke [46]. It is interesting that these smoke free laws decrease smoking prevalence in the general population [47,48]. Furthermore, from observational studies it seems that smoke free laws reduce admission rates for asthma in adults and children [49,50]. It is also important that passive smoking is correlated to poor QoL in asthmatic adolescents, something that makes the implementation of these smoke free laws vital [51].

Smoking cessation is an important clinical strategy that can improve clinical outcomes and QoL and reduce total mortality in patients with asthma [10,52,53]. Chaudhuri, et al., showed improvement in lung function and a reduction in sputum neutrophil count in patients who quit smoking (6 weeks after smoking cessation) compared to patients who continued to smoke [54]. Smoking cessation improved clinically important parameters such as airway hyperresponsiveness and symptom score in asthma patients’ aged from 19 to 40 years [55].

Despite the harmful effects of smoking on patients with asthma, a significant proportion of asthmatics remain smokers. It seems that it takes HCPs 17 years to convince asthmatics who smoke to quit [56] and that they do not have expertise in smoking cessation and lack engagement in order to help these patients [57]. Studies have shown that the prevalence of smoking among patients with asthma is very similar to that of the general population [58,59]. However, limited data are available on the impact of smoking in patients with severe asthma. Furthermore, smoking asthmatics are often excluded from asthma randomized controlled trials, limiting the information available to assess relative effectiveness of different treatment options for disease management in these patients [60]. Additionally, asthmatic smokers are still not fully aware of the effect of smoking on their disease. Namely, more than 40% believe that smoking does not worsen their asthma [61]. Many believe that the damage has done and therefore, there is little point in attempting to quit smoking or they
have never received support for smoking cessation, or raised concern about the perceived health risks of pharmaceutical treatment [62], for smoking cessation.

Here, we present findings from the Still Fighting for Breath II global survey [63], regarding the prevalence of smoking in patients with severe asthma, impact of smoking on asthma control and correlation of smoking with different aspects of QoL in patients with severe persistent asthma.

Methods

Participants

Still Fighting for Breath II survey included patients with severe persistent asthma. Adult patients (>18 years) and caregivers of pediatric and adolescent patients (6-17 years) from nine countries were enrolled in this survey. Patients invited to complete the screening questionnaire were mainly identified via databases (consumer panels) [63].

Survey description

Survey description is previously explained in a report by Katsaounou, et al. [63]. For this analysis, specific information on current smoking status was collected among adult patients; individuals were identified as current smoker, ex-smoker, e-cigarette smoker and non-smoker. Questions regarding dual smokers or ex-smokers who were e-cigarette smokers were not included in the questionnaire. Further, among smokers, also number of cigarettes per day was collected among adult patients.

Results

Participants

A total of 1333 patients with severe persistent asthma were surveyed, of whom 1181 were adults and 152 were caregivers of pediatric and adolescent patients; the patient distribution and demographics is previously described in a report by Katsaounou, et al. [63]. The majority of adult patients (56%) were women. The demographics of the population is given in supplementary (S1).

Smoking status

Of the adult patients, 46% were either current smokers (20%), ex-smokers (24%) or e-cigarette (2%) smokers while 54% of patients reported to have never smoked (Figure 1). Interestingly, the proportion of patients with asthma who smoked was higher than that in the general population in many countries (Table 1).

Avoidance of public places

Overall, 63% of adult patients avoided smoky premises; however, 20% of adults were active smokers.

Correlation between smoking and psychological condition

Current smokers with asthma were significantly more frequently diagnosed with anxiety (47%) and depression (41%) than never-smokers (40% and 27%, respectively) and ex-smokers (42% and 28%, respectively) (z-test, =0.05).

Contributions of smoking to asthma control and psychological condition

There is a weak effect of smoking on asthma control independently of anxiety/depression, but this variable does not take into account the degree of smoking that may be of importance. We stress that this survey was not designed to address the issue and we do not have information about the level of smoking in asthma patients (Figure 2).

Mediation analysis: The numbers between the variables is the beta weight in a linear regression, showing the degree of relationship between those variables. The number in brackets between anxiety/depression and asthma control (GINA) is the beta weight between these two variables after removing the
common variance of the smoking variable. The number in brackets between smoking and asthma control (GINA) is the beta weight between these two variables after removing the common variance of anxiety/depression.

**Oral corticosteroid use:** Among adult patients, smokers received treatment with an oral corticosteroid (OCS) for an average of 21 days in the previous 6 months; never-smokers received OCS treatment for 19 days during the same period (Table 2). A positive correlation was observed between the number of days that patients with severe asthma used OCS and asthma control according to both the Global Initiative for Asthma (GINA)-defined control (Spearman’s rho=0.24, P<0.001) and patient-perceived control (Spearman’s rho=0.13, P<0.001).

**Discussion**

Overall, the survey showed that smoking was common in asthma patients with 66% of adult patients either current smoker, ex-smoker or e-cigarette smokers. A recent report by Pinheiro, et al., shows that former and current smoking is associated with severe asthma. Longer smoking history was observed in the group of patients with severe asthma (former smoker, 4.4 pack-years; current smoker, 25.5 pack-years) when compared with that of those with mild-to–moderate asthma (former smoker, 1.2 pack-years; current smoker, 1.3 pack-years) [64]. In our survey, the proportion of patients with asthma who were current smokers, ex-smokers or e-cigarette smokers was higher than in the general population in many countries [65,66]. Previous studies have shown that the prevalence of smoking is similar in general population compared with asthmatic population [67,68]. A cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries observed that significant proportion of patients with severe asthma also smoke [69]. It should be noted that in our survey, majority of adult patients avoided smoky places, suggesting awareness of the impact of passive exposure to smoking on asthma. Notably, approximately 20% of this population were active smokers.

We found that a higher proportion of patients who were current smokers were diagnosed with psychological conditions such as anxiety and depression when compared with never-smokers [13]. Psychological disorders such as anxiety and depression in patients with asthma are known to be associated with more severe and uncontrolled asthma and to affect the QoL of these patients [67,70]. Our correlation analysis showed that both anxiety/ depression and smoking independently contribute (although weak correlation) to poor asthma control in patients with severe asthma. However, no direct correlation between smoking and depression/ anxiety was observed in our study, which is in line with previous reports [71].

The association between smoking and poor asthma control has been reported; Schatz, et al., reported that smoking was significantly and inversely related to long-term control of asthma [72]. Another survey conducted in asthmatic patients in the US showed that patients who are current smokers report more asthma attacks and nocturnal symptoms compared with non-smokers [5]. Boulet, et al., reported that current smokers are significantly more likely to experience day–time symptoms when compared to former or non-smokers [73]. Furthermore, higher number of smoking pack-years is correlated with more frequent hospitalization and higher number of comorbidities [12]. However, studies have shown that many asthma patients who smoke are not aware or underestimate the contribution of smoking to their worsened asthma symptoms [61,74,75]. Smokers compared to non-smokers report lower scores in recognizing the association between smoking and asthma symptoms [75]. In our survey there is a weak effect of smoking on asthma control independently of anxiety/depression, but this variable does not take into account the degree of smoking, which is important.

Eosinophilic inflammation has been long implicated in the pathogenesis of asthma. However, in addition to eosinophilic inflammation smoking asthmatics show neutrophilic airway inflammation [25]. In fact, Wenzel, et al. (2012) discussed the possibility of considering smoking-induced neutrophilic asthma as a distinct phenotype [26]. Never smokers and ex-smokers with severe asthma express different predictors of frequent exacerbations with higher blood neutrophils observed in ex-smokers and higher blood eosinophils in never smokers. Thus suggesting different types of systemic inflammation pathway play a role in the aetiology of exacerbations in these two groups of patients [76]. Although ICS is an effective treatment option in management of patients with mild–to–severe persistent asthma, studies have reported impaired efficacy of corticosteroids in asthma patients who smoke [23,77,78]. This decreased efficacy may be due to increased oxidative stress as a result of increased neutrophils and macrophages, an innate immune response to cigarette smoke-induced tissue damage [29]. In our survey as well, a slightly higher use of corticosteroids was observed in current smokers compared with never-smokers, indicating greater severity of disease in smokers. This increase in use of corticosteroids may also be attributed to steroid resistance [23]. Higher neutrophil levels is associated with severe airway hyper responsiveness after treatment with ICS in ex- and current smokers with

<table>
<thead>
<tr>
<th>Table 2: Days of oral corticosteroid use in the previous 6 months by smoking status in adult patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking status</td>
</tr>
<tr>
<td>Current Smoker</td>
</tr>
<tr>
<td>Ex-smoker</td>
</tr>
<tr>
<td>E-cigarette smoker</td>
</tr>
<tr>
<td>Never-smoker</td>
</tr>
</tbody>
</table>

Citation: Katsaounou P, Ioannou M, Hyland ME, Odemuyr M, Spranger O, et al. (2019) Smoking asthmatics, a neglected large phenotype of asthmatic patients. Open J Asthma 3(1): 001-008. DOI: https://dx.doi.org/10.17352/oja.000010
asthma [79]. Furthermore, increase in FEV1 after 2-week ICS-therapy was observed in patients with lower blood neutrophils [80]. Thus suggesting that higher blood neutrophil levels is associated with less clinical ICS-response in ex- and current smokers with asthma. Chaudhuri R, et al., reported that a combination therapy of budesonide/formoterol (160/4.5 μg) in patients with asthma who were symptomatic despite treatment with ICS with or without long-acting β2-agonists (LABAs) showed significant improvement in QoL in terms of Asthma Control Questionnaire (ACQ)-5 scores in non-smokers compared with smokers. However, a higher treatment dose exhibited similar reduction in ACQ-5 scores in smokers and never-smokers [81]. Although cigarette smoking is associated with decreased response to steroid therapy, there is no guideline for optimal pharmacological treatment of smokers/smoking asthmatics. Conventional strategies for disease management include smoking cessation, dose escalation and implementation of laws banning smoking in public spaces [24,46,82].

Fighting for breath survey conducted by European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) between 2004 and 2005 reported that passive smoking was considered as one of the major reasons for poor quality of life in patients with severe asthma [66,80,83]. Though various steps have been taken to improve the quality of life of asthma patients including implementation of laws banning smoking in public spaces [84], our survey findings show that smoking still prevails in patients with asthma resulting in poor QoL. Therefore, there is an urgent need to revisit treatment strategies, integration of smoking cessation strategies into asthma care and introduce new treatments for effective management of disease and better quality of life in these patients.

Limitations

This was an online survey, hence the data were self-reported by patients and were not clinically verified; thus, inaccurate responses due to poor recall cannot be excluded. Moreover, it is difficult to accurately predict the actual factors behind participant responses. Our survey was not designed to determine if patients were on the right treatment as per the disease severity and were adherent to treatment, thus influencing their responses. Additionally, the intensity of smoking (pack per day) was not investigated.

Conclusion

Our survey shows that smoking is still common in patients with severe asthma and is associated with increased risk of anxiety/depression and show slight increase in use of oral corticosteroid. Thus, there is a need for improved management and support (smoking cessation, new treatments, assessment of psychological conditions) of smokers with severe persistent asthma.

Acknowledgement

The authors thank Jisha John (PhD) and Rahul Lad (PhD) of Novartis, Hyderabad, India for providing medical writing support/editorial support, which was funded by Novartis, in accordance with Good Publication Practice (GPP3) guidelines.

Funding

The study was funded by Novartis Pharma AG, Basel, Switzerland.

Conflict of interest

MEH, MO, OS, AL, MG have no competing interests. LCG, XJ are employees of Novartis. IK was an employee of Novartis at the time of conduct of the survey. PK was an ERS research fellow in Novartis at the time of the survey.
References


Citation: Katsaounou P, Ioannou M, Hyland ME, Odemry M, Spranger Q, et al. (2019) Smoking asthmatics, a neglected large phenotype of asthmatic patients. Open J Asthma 3(1): 001-008. DOI: https://dx.doi.org/10.17352/oja.000010


